COVID-19 Weekly Data

Division of Epidemiology
Public Health Services
11/08/2021
Vaccine effectiveness adjusted for sex and week, 20 Jun – 07 Aug, 12-15 years old using person-time incidence model published in Lancet\textsuperscript{1}

<table>
<thead>
<tr>
<th>Outcome</th>
<th>20/06-07/08</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>VE</td>
</tr>
<tr>
<td>SARS-CoV-2 infections</td>
<td>87.7%</td>
</tr>
<tr>
<td>Symptomatic COVID-19*</td>
<td>90.9%</td>
</tr>
</tbody>
</table>

* Fever and/or respiratory symptoms on epidemiologic investigation

Breakthrough SARS-CoV-2 infections by week of diagnosis and month of vaccination, 16-59

Note: 3rd dose recipients removed from numerator and denominator
Breakthrough SARS-CoV-2 infections by week of diagnosis and month of vaccination, 60+

Note: 3rd dose recipients removed from numerator and denominator
Point estimates and 95% confidence intervals
SARS-CoV-2 breakthrough infection rate
1 Aug – 8 Aug 2021

Note: 3rd dose recipients removed from numerator and denominator
Severe breakthrough COVID-19, 60+
by week of infection and month of second dose

NOTES:
3rd dose recipients removed from numerator and denominator.
This accounts for the decrease in cases during the week of 1 Aug – 7 Aug 2021
Patients diagnosed in last week may not have sufficient follow-up time to develop severe disease
Adjusted vaccine effectiveness against severe COVID-19, 65+ stratified by month of second dose, 20 Jun – 07 Aug 2021

Vaccine effectiveness against severe COVID-19 by month of second dose, 65+ (without booster)
20/06-07/08/2021

* Adjusted for age group (65-74, 75-84, 85+), sex and week
SARS-CoV-2 infection rates by date of diagnosis and vaccine status, 55+

Daily SARS-CoV-2 incidence rates by vaccine status
55 years and over

Unvaccinated  2nd dose  3rd dose

29/7 3rd dose approved for 60+

Rate per 1,000,000
7-day moving average

Date of diagnosis
Severe COVID-19 rates by date of diagnosis and vaccine status, 55+